- Home
- MED vs URGN Comparison
MED vs URGN Comparison
Compare MED & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- URGN
- Stock Information
- Founded
- MED 1980
- URGN 2004
- Country
- MED United States
- URGN United States
- Employees
- MED N/A
- URGN N/A
- Industry
- MED Packaged Foods
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- URGN Health Care
- Exchange
- MED Nasdaq
- URGN Nasdaq
- Market Cap
- MED 152.3M
- URGN 181.2M
- IPO Year
- MED N/A
- URGN 2017
- Fundamental
- Price
- MED $14.58
- URGN $12.95
- Analyst Decision
- MED Hold
- URGN Strong Buy
- Analyst Count
- MED 1
- URGN 8
- Target Price
- MED $16.50
- URGN $23.00
- AVG Volume (30 Days)
- MED 279.2K
- URGN 5.5M
- Earning Date
- MED 08-04-2025
- URGN 08-12-2025
- Dividend Yield
- MED N/A
- URGN N/A
- EPS Growth
- MED N/A
- URGN N/A
- EPS
- MED N/A
- URGN N/A
- Revenue
- MED $543,452,000.00
- URGN $91,871,000.00
- Revenue This Year
- MED N/A
- URGN $36.65
- Revenue Next Year
- MED N/A
- URGN $88.35
- P/E Ratio
- MED N/A
- URGN N/A
- Revenue Growth
- MED N/A
- URGN 8.98
- 52 Week Low
- MED $11.57
- URGN $3.42
- 52 Week High
- MED $22.66
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- MED 60.09
- URGN 63.17
- Support Level
- MED $12.95
- URGN $12.73
- Resistance Level
- MED $14.90
- URGN $13.93
- Average True Range (ATR)
- MED 0.67
- URGN 1.24
- MACD
- MED 0.12
- URGN -0.00
- Stochastic Oscillator
- MED 83.98
- URGN 50.49
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.